PROTACs: Walking through hematological malignancies.

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Proteolysis targeting chimeras (PROTACs) are heterobifunctional molecules that hijack the ubiquitin-proteasome system for targeted protein degradation.
• PROTACs offer a unique therapeutic modality, capable of targeting proteins resistant to conventional inhibition, including those with mutations.
• Their efficacy and specificity in degrading oncogenic drivers make them a promising avenue for novel anticancer drug development.

Purpose of the Study:

• To provide a comprehensive overview of recent developments in PROTAC technology for hematologic malignancies.
• To focus on clinically relevant PROTACs and strategies targeting therapy-resistant oncogenic mutations.
• To discuss current limitations and optimization considerations for PROTAC design.

Main Methods:

• Literature review of recent advances in PROTAC development.
• Analysis of PROTAC applications in preclinical and clinical studies for hematologic cancers.
• Focus on PROTACs targeting specific oncogenic drivers and resistance mechanisms.

Main Results:

• PROTACs demonstrate significant potency and selectivity in degrading oncogenic proteins across various hematologic malignancies.
• Several PROTACs have progressed to advanced clinical trials, showing promise as targeted anticancer therapeutics.
• PROTACs are effective against previously undruggable targets and mutated proteins driving therapeutic resistance.

Conclusions:

• PROTACs represent a rapidly advancing therapeutic strategy for hematologic malignancies, offering new hope against resistant cancers.
• Further optimization of PROTAC design is crucial for maximizing their clinical efficacy and overcoming existing limitations.
• The selective degradation of oncogenic drivers by PROTACs holds substantial potential for future cancer therapy.